Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022

SUNNYVALE, Calif., Nov. 28, 2022 /PRNewswire/ -- Accuray Inc. (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers. According to the IMV ServiceTrak™ Radiation Oncology 2022 report, Accuray achieved the highest score in the industry in Overall Service Performance and was recognized for Best Service in Radiation Oncology. The IMV report includes feedback on radiation therapy technologies used in treating cancer patients in the U.S. and specifically, survey respondents with hands-on experience using Accuray radiation therapy delivery systems.

The Accuray Service team is dedicated to ensuring our customers are successful with our products. According to ServiceTrak, Accuray also achieved the highest ratio of customers highly satisfied with Field Service Engineers Overall and top scores in related categories: Service Follow-Up, Field Service Engineer Competence and Timely Phone Response. Customers also gave Accuray the highest score for Overall Manufacturing Performance.

Specifically, CyberKnife^® and TomoTherapy^® platform customers*:

• Value the support they receive from Accuray employees: “Accuray is always available. There has never been once when we have reached out and not gotten somebody. [The Engineer] provides us with his direct line so we have service satisfaction that no one can meet.” “They have great equipment and service is good and installation is awesome. The whole team is awesome to work with. Even post-installation.”
• Appreciate the entire Accuray experience: “They come up with new technologies. Easy to use system.” “They treat linear tumors better than any machines I know of.” “Accuray by far has been the easiest machine to learn to work on.”

“Our goal is to provide our customers with more than just a machine. We strive to build partnerships that continue throughout the life of our products and create confidence in our organization and our team – through upgrade paths that keep customers on the forefront of technology, service that never quits, and ongoing opportunities for education,” said Scott Chapman, senior vice president, global service at Accuray. “According to IMV, this most recent report marks the third consecutive year we have seen an increase in the percent of customers likely to repurchase an Accuray radiation delivery system, suggesting the company’s focus and our team’s commitment to excellence in meeting customers’ needs is on track.”

Accuray has a history of innovation spanning more than 25 years, culminating in increasingly powerful and flexible options for our customers to make precise radiation treatments available to more patients. Upgrades to the CyberKnife and TomoTherapy platforms, in the form of the CyberKnife S7™ and Radixact^® Systems, and development of the full spectrum of adaptive solutions including intra-fractional adaption with Synchrony^® and inter-fractional offline adaptation (with PreciseART^®), demonstrate a relentless focus on providing clinically relevant, leading-edge technologies designed to change patients’ lives for the better.

*IMV ServiceTrak™ Radiation Oncology 2022 report

About IMV
IMV Medical Information Division, part of Science and Medicine Group, specializes in researching medical imaging and other advanced healthcare technology markets. IMV’s ServiceTrak™ annual series of reports benchmark and monitor customer satisfaction with equipment manufacturers, system performance by product type, and service providers.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit https://www.accuray.com/ or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement
The statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, Accuray’s ability to continue to meet the service needs of its customers. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company’s assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company’s ability to achieve widespread market acceptance of its products; the company’s ability to develop new products or improve existing products to meet customers’ needs; the company’s ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading “Risk Factors” in the company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2022, and as updated periodically with the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-receives-imv-award-for-best-in-service-in-radiation-oncology-for-2022-301687488.html

SOURCE Accuray Incorporated